Temperature-controlled storage and transport for vaccines, biologics, insulin, blood products and diagnostics: market size, drivers (biologics, GLP-1s, cell and gene therapy), GDP compliance, the Gulf as a hub, India’s build-out, key players and what hospitals should audit.
Healthcare cold chain logistics — temperature-controlled warehousing, transport and monitoring for pharmaceuticals, vaccines, biologics, blood products and diagnostics — is growing faster than general pharma logistics because the product mix is shifting to temperature-sensitive biologics and specialty medicines. Published estimates for the 2025 global market range from USD 18.7 bn to USD 24.4 bn; our central estimate is USD 21.5 bn, growing at about 7% to USD 34.5 bn by 2032.
The Gulf is investing to become a pharma logistics hub between Asia, Europe and Africa (Dubai Airport Freezone and Jebel Ali, Riyadh and the new NUPCO network); India is building GDP-compliant capacity for exports and for domestic biologics and vaccines. Inside hospitals, the cold chain is the most frequent audit failure: temperature logging, excursion handling and last-mile storage for high-value biologics.
The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 18.7 bn–USD 24.4 bn; differences are mostly scope.
| Publisher (date) | Base value | Forecast | CAGR |
|---|---|---|---|
| Credence Research (2026) — Global pharma cold chain logistics (transportation, packagin | USD 24.35 bn (2025) | USD 48.71 bn (2035) | 7.18% (2026-2035) |
| IMARC Group (2026-02) — Global healthcare cold chain logistics (biopharma, vaccines, | USD 18.7 bn (2025) | USD 23.8 bn (2034) | 2.66% (2026-2034) |
| Technavio (2026-03) — Global pharma cold chain logistics; YoY growth 2025-26 of 9. | None (2025) | incremental growth USD 16.76 bn (2026-2030) (2030) | 10.4% |
| Mordor Intelligence (2026) — India healthcare cold chain logistics; 2026 est. USD 9.27 bn | USD 8.72 bn (2025) | USD 12.40 bn (2031) | 5.99% (2026-2031) |
| Astute Analytica (2024) — Middle East healthcare logistics (all temperatures; ambient | USD 4.51 bn (2023) | USD 8.67 bn (2032) | 7.95% (2024-2032) |
| Consulting Wallah central estimate | USD 21.5 bn (2025) | USD 34.5 bn (2032) | ~7% |
Source: Publisher pages as listed under Sources; CW estimate as described in Method.
Included: 2–8 °C, frozen and ultra-cold storage, transport (air, road, sea), packaging and monitoring for healthcare products, provided by 3PLs, forwarders, distributors and in-house operations. Excluded: food cold chain; ambient pharma logistics (reported as context). Standards: WHO GDP, EU GDP, GDP certifications (IATA CEIV Pharma).
Shares as reported by the named sources; ranking is more reliable than the exact percentage.
| Segment | Share | Note | |
|---|---|---|---|
| North America | 38% | 6.71% CAGR | |
| Europe | 28% | 6.51% | |
| Asia Pacific | 24% | 8.41%, fastest | |
| Latin America | 5% | 7.61% | |
| Middle East & Africa | 5% | 7.81% |
Source: Credence Research
| Segment | Share | Note | |
|---|---|---|---|
| Transportation | 52% | largest |
Source: Credence Research
| Segment | Share | Note | |
|---|---|---|---|
| Biologics | 46% | largest |
Source: Credence Research; Technavio
| Segment | Share | Note | |
|---|---|---|---|
| Road | 48% | largest |
Source: Credence Research
| Segment | Share | Note | |
|---|---|---|---|
| Transportation (function) | 52.47% | VAS fastest 6.74% | |
| Chilled 2-8C (temperature) | 46.11% | Frozen fastest 9.91% | |
| Pharmaceuticals (product) | 36.2% | Biopharma fastest 12.05% | |
| Domestic (destination) | 84.03% | International 7.05% CAGR | |
| Pharma manufacturers (end user) | 32.78% | Biopharma mfrs fastest 6.63% | |
| West India (geography) | 29.4% | South fastest 7.29% |
Source: Mordor Intelligence
| Segment | Share | Note | |
|---|---|---|---|
| Saudi Arabia | 36.98% | largest country | |
| Pharmaceuticals (product) | 51.67% | ||
| Services | 50.86% | ||
| Pharmacies (end user) | 44.53% | ||
| Ambient (temperature) | 43% |
Source: Astute Analytica
| Axis | Segment | Figure | Note |
|---|---|---|---|
| by service type (global, 2025) | Packaging solutions | fastest | 7.78% CAGR |
| by application (global, 2025) | Clinical trial materials | fastest | 7.75% CAGR |
| by application (global, 2025) | Vaccines | USD 10.76 bn (2024) | Technavio: largest product segment |
| by mode of transport (global, 2025) | Sea | fastest | 7.89% CAGR |
| Middle East healthcare logistics (2023 share) | UAE | second | None |
Source: As listed under Sources.
| Country / region | Figure | Year | Source |
|---|---|---|---|
| Middle East healthcare logistics | USD 4.51 bn (2023) -> USD 8.67 bn (2032), 7.95% CAGR | 2023 | Astute Analytica |
| Middle East & Africa share of global pharma cold chain | 5.0% (2025), 7.81% CAGR | 2025 | Credence Research |
| India healthcare cold chain logistics | USD 8.72 bn (2025) -> USD 12.40 bn (2031) | 2025 | Mordor Intelligence |
| APAC share of global growth (pharma cold chain) | 34.9% of incremental growth, fastest region | 2026-2030 | Technavio |
| Saudi Arabia share of Middle East healthcare logistics | 36.98% | 2023 | Astute Analytica |
Source: Sources as named; see Sources and method.
Dubai (DAFZA, Jebel Ali, Emirates SkyCargo pharma corridor) and Abu Dhabi (Etihad Cargo, HOPE Consortium legacy capacity) compete as hubs; Saudi Arabia’s NUPCO network and new 3PL capacity serve public tenders; distributors are investing in GDP warehouses.
Vaccine exports (Serum Institute, Bharat Biotech), biosimilars and insulin drive GDP-grade capacity (Snowman, Kool-ex, DHL, Kuehne+Nagel, Blue Dart); domestic hospital last-mile remains weak outside metros.
| Date | Development | Source |
|---|---|---|
| 2026-07 | DHL plans ~USD 2.25 bn investment in health logistics by 2030; FedEx healthcare transport revenue reached nearly USD 10 bn in FY2026; C.H. Robinson passed USD 1 bn healthcare logistics revenue. | Becker's Hospital Review (citing CNBC) |
| 2026-06 | UPS announced ~USD 48 mn for 27 temperature-controlled facilities to serve GLP-1/biologics demand; UPS healthcare hit USD 3 bn quarterly revenue. | Fortune |
| 2026-05 | CONCOR, Maersk and South Central Railway launched the Aushadhi Express pharma reefer rail service (Hyderabad-JNPT); Kuehne+Nagel opened a HealthChain-certified cross-dock in Hyderabad. | Mordor Intelligence |
| 2026-02 | FedEx broke ground on an INR 2,500 crore automated air cargo hub at Navi Mumbai airport; DHL announced expansion of its dedicated airfreight cold chain network with India as a priority market. | Mordor Intelligence |
| 2026-01 | UPS acquired European cold-chain specialists Frigo-Trans and BPL, following its USD 1.6 bn Andlauer Healthcare Group acquisition (Nov 2025). | Fortune |
| 2025-03 | DHL acquired CRYOPDP, adding life-sciences and advanced-therapy (cryogenic) logistics capabilities. | Mordor Intelligence |
Source: Company and press announcements as named.
Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.
Published estimates normalised to 2025 range from USD 18.7 bn to USD 24.4 bn. Consulting Wallah’s central estimate is USD 21.5 bn in 2025, rising to about USD 34.5 bn by 2032.
Published CAGRs range from 2.66% to 7.18%; our central case is about 7% a year to 2032.
DHL Group (DHL Supply Chain / Global Forwarding, CRYOPDP), Kuehne+Nagel, UPS Healthcare (incl. Andlauer, Frigo-Trans, BPL), FedEx (Life Sciences organization), DSV, CEVA Logistics, DB Schenker, C.H. Robinson among others.
The summary on this page is free to read and share with attribution. The full report is free for hospital leaders and registered Consulting Wallah Network members, and priced on request for others.
The full report (PDF, 40 pages) adds the GCC and India deep-dives, hospital-level benchmarks from the Consulting Wallah Network and the full source tables. Free for hospital leaders and registered network members; otherwise priced on request.
How to read these figures. Published market-size estimates for this market vary widely because publishers define scope differently (software only vs software + services + logistics). Where we show a Consulting Wallah estimate we state the range of published figures it is triangulated from and our scope. Figures marked as reported are quoted from the named source. Nothing here is investment advice.